Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air
NCT ID: NCT05680831
Last Updated: 2023-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
60 participants
INTERVENTIONAL
2022-10-13
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air at Rest
NCT06943989
Air Pollution Study: The Effect of Ozone on the Lung
NCT02673775
Acute Health Effects of Ozone Exposure
NCT03697174
The Role of Macrophage Activation in Lung Injury Following Ozone Exposure
NCT05794087
Human Biological Responses to Low Level Ozone
NCT02857283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.070 ppm ozone concentration
Exposure to 0.070 ppm ozone for 6.6 hours while performing moderate intermittent exercise.
0.070 ppm ozone concentration
The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
Clean air (0.0 ppm ozone)
Exposure to clean air (0.0 ppm ozone) for 6.6 hours while performing moderate intermittent exercise.
Clean air (0.0 ppm ozone)
Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.070 ppm ozone concentration
The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
Clean air (0.0 ppm ozone)
Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Physical conditions allowing sustained moderate exercise for 6.6 hours.
3. Normal lung function (NHANES III):
1. FVC \> 80 % of that predicted for gender, ethnicity, age and height.
2. FEV1 \> 80 % of that predicted for gender, ethnicity, age and height.
3. FEV1/FVC ratio \> 80 % of predicted values
4. Oxygen saturation \> 94 %.
5. Total symptom Score no greater than 20 (out of a possible 60-see accompanying score sheet) with a value no greater than 3 for any one score. No more than one score may be equal to 3.
Exclusion Criteria
2. Individuals who are not "up to date," \[meaning a person has received all recommended COVID-19 vaccines, including any booster dose(s) when eligible with their COVID vaccines as defined by the CDC.\]
3. A history of acute and chronic cardiovascular disease, chronic respiratory disease, diabetes,rheumatologic diseases, immunodeficiency state.
4. An acute respiratory illness within 4 weeks.
5. Subjects who are asthmatic or have a history of asthma.
6. Allergic to chemical vapors or gases.
7. Any allergic symptoms during the time of participation in the study
8. Female subjects who are currently pregnant, attempting to become pregnant or breastfeeding
9. Subjects currently taking mega doses of vitamins and supplements, homeopathic/naturopathic medicines or medications which may impact the results of the ozone challenge or interfere with any other medications potentially used in the study (to include systemic steroids and beta blockers). Medications not specifically mentioned here may be reviewed by the investigators prior to a subject's inclusion in the study.
10. Current and past smokers within 2 years, or subjects with a smoking history of at least a pack of cigarettes a day for more than 10 years over your lifetime. This includes vaping, hookah,and e-cigarettes.
11. Uncontrolled hypertension (\> 140 systolic, \> 90 diastolic). Blood pressure readings equal to or greater that 140 Systolic and equal to or greater that 90 diastolic.
12. Subjects who do not understand or speak English
13. Unspecified illnesses, which in the judgment of the investigator might increase the risk associated with ozone inhalation challenge or exercise, will be a basis for exclusion.
1. Individuals who have had an acute respiratory illness within 4 weeks.
2. Individuals who have active allergies.
3. Individuals that have engaged in strenuous exercise within 24 hours of any study visit.
4. Individuals unable to avoid drinking alcohol for 24 hours prior to all study visits.
5. Individuals who have been exposed to smoke and fumes for 24 hours before all visits.
6. Individuals that have used an ozone-based home air purifier for 24 hours before all visits.
7. Individuals that have eaten or drank anything for 2 hours prior to the sputum training/screening day visit.
8. Individuals should avoid caffeine for 12 hours prior to all study visits.
9. Individuals should refrain from all over the counter anti-inflammatory agents including those for allergies, and anti-inflammatory drugs or antioxidants for a period of one week prior to the train and to the exposure.
10. Individuals that have been exposed to or have consumed any agent or have undertaken any activity within 24 hours of any study visit that the investigators believe may compromise the results of the study.
\-
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of North Carolina
OTHER
Martin W. Case
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Martin W. Case
Clinical Studies Coordinator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andy Ghio, M.D.
Role: PRINCIPAL_INVESTIGATOR
EPA/ORD/CPHEA/PHITD/CRB
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
EPA Human Studies Facility
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB# 21-3193
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.